Michael Petroutsas, Senior Vice President and Head of GSK’s US Oncology Business Unit, talks about how his background has taught him the importance of connecting with patients on their level and how he brings that mentality to GSK.

Episode 93: Cultural Cues in Oncology

Jeff Stoll, US Life Sciences Strategy Leader at KPM, talks about some of the highlights from KPMG’s recent Global Pharma CEO Outlook report.

Episode 95: CEOs Share Their Industry Outlook

Biolumina's Troy Clark, SVP, Creative Director, and Anne Brown, SVP, Creative Director, Copy discuss their APEX-award winning website "Be in the Know" for AstraZeneca's metastatic non-small cell lung cancer (NSCLC) disease state education efforts.

Behind the Creative...Inspiring Award Winning Creative with Troy Clark and Anne Brown

Carolyn O’Neill, Chief Creative Officer of Centron discusses their APEX-award winning global disease awareness campaign for both HCPs and patients, “Dimensionalizing the Patient Experience in PNH.” PNH or paroxysmal nocturnal hemoglobinuria is a rare immune disorder that attacks a person’s red blood cells. The campaign was meant to build on it is not an inherited disease and people’s symptoms don’t exhibit externally, usually appearing in mid-life and portray the feelings of a PNH sufferer.

Behind the Creative…Inspiring Award Winning Creative Carolyn O’Neill

In episode 121 of the Pharm Exec Podcast, Nathalie Dompé, co-CEO of Dompé Pharmaceuticals, shares a glimpse into her journey in the pharma industry, her leadership style, the differences in working in leadership in the United States vs. Europe (Italy, specifically), and technologies in the biopharma industry. Meg Rivers, editor-in-chief, and Miranda Schmalfuhs, group social media editor, also talk to Dompé about: 1) launching a rare disease drug in the United States, the commercial/sales/marketing challenges, and what the company learned in the process; 2) how launching a rare disease drug differs from other drugs as it relates to the commercialization phase; 3) how can the industry can best meet the needs of patients and health systems; 4) balancing family/home life and work.

Leadership in the US vs. Europe and Launching a Rare Disease Drug

On this week’s episode, Meg Rivers, editor-in-chief, and Miranda Schmalfuhs, group social media editor, speak with Steve Paul, chairman of the board, president, and CEO of Karuna Therapeutics, as well as Andrew Miller, founder and chief operating officer of Karuna Therapeutics. Miller was also one of Pharm Exec’s 2020 Emerging Pharma Leaders.

The editors speak with Paul and Miller about the following: 1) their journey into pharma; 2) the factors that impact their decision to pursue any individual drug product; 3) the mental health/disorder treatment landscape; 4) what treatment has been like, historically, for schizophrenia and psychosis in Alzheimer's disease; 5) the company’s drug, KarXT, which is being evaluated in schizophrenia and psychosis in Alzheimer's disease; and 6) potential marketing and commercialization challenges for KarXT.

The Gap In Mental Health Treatments: Schizophrenia

Cell and gene therapies are at the tip of everyone’s tongues in biopharma. Significant headway has been made in this space, though there is more research that needs to be done and many more therapeutic areas to eventually apply this method of treatment to. Chris Fox, president of Novartis Gene Therapies, shares insights into her work with gene therapies and discusses commercialization challenges. Through its gene therapies business, Novartis builds on the capabilities created through its experience with Zolgensma, a gene therapy for spinal muscular atrophy. Fox also dives into how she entered the pharma space, her role at Novartis, balancing work and home life, and what the Novartis team is most proud of from 2022 as well as what they are most excited about in 2023.

Gene Therapies: 2023 Predictions and Commercialization Challenges

It is no easy feat to break into a male-dominated field as a woman, no less the bio/pharmaceutical industry. Piper Trelstad, PhD, head of chemistry, manufacturing, and control (CMC), Bill & Melinda Gates Medical Research Institute, shares with Meg Rivers, editor-in-chief of Pharmaceutical Executive, her experiences working in the industry, specifically in the vaccines space, as well as what it was like for her moving up the ranks as a woman. Other topics discussed include Trelstad’s predictions for more women working at the C-suite level, the inner workings of the Bill & Melinda Gates Medical Research Institute (including work on an infant probiotic), insight into her personal journey, and more.

Working In A Male-Dominated Field

In his position, Faruk Capan leads thousands of employees around the globe with a focus on bold innovation—one can imagine how excited he is about Chat GPT, which set the record for fastest-growing user base in history. Senior editor Fran Pollaro and Faruk go back and forth about positives, negatives, hopes, and fears attached to generative AI for us as regular humans, and as pharma marketers. The pair delve into content creation, creative, video production, research, sales and marketing…it’s clear that we’re on the precipice of life-changing innovation.

The Explosive Arrival of Chat GPT and Generative AI

Join Tina Fascetti, CCO of The Agency Network at MJH Life Sciences for a podcast interview with Ryan Potter, ACD Art, and Priscila Ramos, ACD Copy, from McCann Health as they share the "behind the creative" story of their Apex Award-winning consumer creative campaign for Entresto. The Apex Awards is judged by none other than the people they are aimed to connect with, the patients themselves.

Behind the Creative: Let’s Hear from the Creators

Across most industries, finding and keeping the right talent is a constant challenge for companies. This challenge is perhaps even more prevalent in the pharmaceutical industry, which requires a significant amount of specialization. Rebekah Martin, senior VP of reward, inclusion, and talent acquisition for AstraZeneca, discusses recruiting talent in pharma with Meg Rivers, managing editor. Specifically, Martin talks about 1) her journey into pharma; 2) reasons that finding and keeping talent is a challenge today in pharma; 3) ways to address the need for talent; 4) identifying and nurturing young talent; 5) increasing interest in working in bio/pharma, particularly among students; 6) how talent can be nurtured; and 7)how the industry can support and encourage diversity in the workforce.

Recruiting Talent In Pharma

Cathi Ahearn is a seasoned biotechnology leaders with formative stints at Genentech, Roche, and now at Bristol Myers Squibb, as SVP of worldwide commercial portfolio strategy. Cathi is focused on one goal: shortening the path between creating medical innovation and getting that innovation to patients. Cathi chats with senior editor at Pharmaceutical Executive about her experiences in the past 20+ years and most importantly, the power of cross-functional collaboration, bringing different teams together and tearing down silos that limit the impact new innovations can have for patients.

Tearing Down Silos to Usher Innovative Medicines to Patients Faster

Two companies join forces to unlock the hidden potential in existing drugs to save lives suffering from rare diseases. In 2010, Dr. David Fajgenbaum, co-founder, Every Cure, was a third-year medical student when he became critically ill with Castleman disease (CD). After months of hospitalization and in critical condition, nearly dying several times, he launched an initiative to find treatments to save his life and others. Fajgenbaum and Michelle Longmire, CEO and co-founder, Medable—both physicians and entrepreneurs—team up in a new partnership to treat rare diseases by repurposing drugs that are
already on the market and finding other therapeutic areas where these drugs can have an impact.

Repurposing Drugs - How One Doctor Saved His Own Life And Hopes To Save Others

Elizabeth (Beth) Garner, chief scientific officer for Ferring Pharmaceuticals, speaks with Meg Rivers, managing editor, about: 1) her journey into the world of pharma, including her transition from being a physician/surgeon to working in clinical trials; 2) both women’s and men’s reproductive health; 3) the latest technologies in fertility treatment (for men and women); 4) unmet needs in fertility care; 5) trends in contraception and fertility treatment; 6) DE&I and access to care, and 7) predictions for the contraception and fertility treatment spaces in the coming years

Tackling Reproductive Health And Fertility Care

In this episode of the Pharmaceutical Executive Podcast, we dive into a conversation with Frank Watanabe, president and CEO of Arcutis, a medical dermatology company with a patient-first approach. Discover how Arcutis is transforming the dermatology landscape with its innovative product offerings, such as FDA-approved Zoryve for topical treatment of plaque psoriasis and their upcoming products for seborrheic dermatitis and atopic dermatitis. Learn about the company's guiding principles, the importance of keeping patients at the forefront of decision-making, and the need for further innovation in the dermatology sector after decades of stagnation.

Exploring Arcutis’s Patient - Centric Dermatology Innovations

Launching a drug and receiving approvals—whether it’s in the U.S. or globally—is challenging to navigate. It’s a process that often takes years and a lot of back-and-forth communication with regulatory bodies.  

In this episode, Torrey Cope, partner, food, drug, and medical device practice, Sidley Austin LLP, discusses drug approvals and drug launches from a legal perspective, including 1) his work as an attorney; 2) tips for drug approvals from a legal perspective; 3) current regulatory challenges the industry is facing in the U.S.; 4) the shift away from a one-sized-fits all approach to marketing and global launches; 5) tips for companies navigating the regulatory landscape in the U.S.; 6) when to launch a drug in a country outside of the U.S.; and 7) drug pricing. Join Meg Rivers, managing editor, as she dives into this topic with Cope.

Drug Approvals And Launches From A Legal Perspective

The 2023 Emerging Pharma Leaders share with Meg Rivers, managing editor of Pharmaceutical Executive, and the editorial team what makes a good leader, what has made them the proudest in their career, lessons they wish they had known when starting out, and more.  

Congratulations to the 2023 Emerging Pharma Leaders: Natasha A. Hernday, chief business officer, Seagen; Simon Holland, vice president, women's health commercial lead, Organon; Justin To, chief operating officer, skeletal dysplasias and gene therapy, Bridge Bio; Frank Watanabe, president and CEO, Arcutis Biotherapeutics; and Hanadie Yousef, PhD, co-founder and CEO, Juvena Therapeutics. 

SPONSOR: APEX Awards
https://www.pharmexec.com/apex-awards

Emerging Potential: Changing Lives One Story, One Therapeutic at a Time

This Pharma 50 companion episode delves into the vital topic of trust within the pharmaceutical industry. Morton Nielsen, senior partner for the life sciences practice at Wittkieffer, dissects the concept, drawing on parallels to Maslow's hierarchy of needs, and discusses practical methods for measuring and operationally improving trust. This episode is a must-listen for those interested in understanding the current state and future evolution of trust in the pharmaceutical sector, an industry where trust forms a fundamental pillar for delivering on its mission statement. 

Read the 2023 Pharma 50 article here: https://www.pharmexec.com/view/2023-pharm-exec-top-50-companies

The Trust Imperative: Defining and Building Trust in Pharma

We all know that the pharma industry is about people—bettering the lives of others through good research, life-changing pharmaceuticals, and keeping the patient front and center. But Jag Dosanjh, president, US neuroscience and eye care, AbbVie, lives that principle. In this podcast episode, Meg Rivers, managing editor, talks with Dosanjh about what he calls a “people business” and his approach to leadership. He starts his career in the medical sales space before working in many different roles and therapeutic areas before ultimately landing at AbbVie. He was also nominated HBA’s mentor of the year and shares insights into being a good leader and mentor. One of his tips was: “If you listen well, you can learn well.” In addition, he emphasized the importance of curiosity, learning, and the pursuit of a smile.

Listening is the Key to Good Leadership

Welcome to a riveting episode of the Pharm Exec podcast, where we dive headfirst into the transformative world of AI in healthcare with Sharlene Jenner, vice president of engagement strategy with the award-winning agency Abelson Taylor. This enlightening conversation traverses the advancements and potential risks of AI, the revolution it is stirring in pharmaceutical marketing, and its game-changing role in understanding complex protein structures. Amid the rapid innovation, we explore the urgent need for ethical guidelines and regulations to keep pace with technology.

AI Frontiers: Navigating the Risks, Rewards, and Regulations

In this podcast, Mohit Manrao, the SVP and head of US oncology at AstraZeneca, shares his journey from growing up in Northern India with aspirations of becoming a doctor, to leading oncology initiatives at AstraZeneca in the US. A central strategy to ultimately eliminate cancer includes ensuring that the latest scientific advancements are accessible to patients in every zip code and the necessity of integrating the patient perspective at every stage—from early discovery to commercialization, recognizing the importance of diverse patient needs, non-invasive diagnostics, and alleviating challenges in access to screenings and treatments.

Transforming Cancer Care: Data, AI, and Patient-Centered Care

In this podcast, Sharlene Jenner, vice president of engagement strategy at Abelson Taylor and professor of AI and personalization for digital marketers at Southern Methodist University, leads a panel of five industry leaders in a roundtable discussion. The conversation delves into the practicalities of current AI applications and confronts the ethical and regulatory issues related to the technology. The panelists also explore the direct consequences and prospective implications of AI, providing listeners with a snapshot of the present and an outlook on the transformative potential of emerging technologies in the pharmaceutical marketing sphere. 

The panel consists of: Faruk Capan, chief innovation officer, EVERSANA, and CEO, EVERSANA INTOUCH; Anurag Banerjee, CEO and founder, Quilt.AI; Jeff Headd, vice president, commercial data science, The Janssen Pharmaceutical Companies of Johnson & Johnson; and Stephen Onikoro, senior principal, head of strategy, PharmaForceIQ.

Sponsored by: ZS https://www.zs.com/

Pharma Marketing in the Age of AI: A New Era Begins

How to price a bio/pharmaceutical drug is one of the most complex topics for pharmaceutical executives, as there are many factors to consider. Alice Valder Curran, life sciences regulatory expert and partner, Hogan Lovells LLP, reveals the following to Pharmaceutical Executive® in this exclusive Pharm Exec Podcast interview: 1) the biggest drug pricing challenges today; 2) current efforts to lower drug pricing; 3) what companies should consider as it relates to drug pricing from a legal perspective; 3) the status of the Inflation Reduction Act (IRA), specifically what should companies be watching for; 4) potential impact on companies from the IRA; 5) IRA milestones we will be seeing through the end of the year; and 6) drug pricing recommendations (from a legal perspective).

ACT podcast: https://www.appliedclinicaltrialsonline.com/editorial-podcasts

Drug Pricing Challenges and Navigating The IRA

Gerald Kierce, co founder and CEO of Trustible and Andrew Gamino-Cheong, the company's CTO and co founder, delve into the realm of artificial intelligence discussing Trustible's mission and its pioneering efforts to ensure ethical AI use particularly in the pharmaceutical industry, and how it navigates complex AI regulations across the globe.

Ethical AI Practices

Commercialization is a tough road to navigate even for the most established bio/pharmaceutical therapies. But as cell and gene therapies (CGTs) continue to form roots and make a splash worldwide—but specifically in the US—commercialization forms its own version of standardization and best practices.  

In this exclusive interview with Pharmaceutical Executive, Lung-I Cheng, vice president of CGT, Cencora (formerly AmerisourceBergen), discusses: 
1) defining CGT commercialization strategies and foundational knowledge—and the best music metaphor
2) what he wishes companies knew about commercialization strategies
3) common knowledge gaps of CGTs
4) how CGT developers can overcome key challenges, including those related to patient access, regulatory requirements, and market access
5) how planning for allogeneic cell therapies differs from autologous cell therapies and gene therapies
6) how companies can demonstrate CGT value as more products enter the development pipeline (and competition intensifies)
7) when to start planning a CGT commercialization strategy
8) predictions for the CGT market in five years

Avoiding Commercialization Pitfalls for CGTs

In this exclusive Pharm Exec Podcast episode with Paul Biondi, executive partner at Flagship Pioneering (the venture creation firm behind Moderna and many other life science firms) and president of Pioneering Medicines, Meg Rivers, managing editor, asks Biondi about 1) the process of founding a company; 2) what factors they consider when deciding whether to partner with a pharmaceutical company (like your partnership with Novo Nordisk) or a foundation (like your partnership with the Cystic Fibrosis Foundation)—along with what makes one organization stand out from another; 3) where science is booming in pharma right now; 4) deciding whether to found a company looking to launch innovations in an existing space vs. pursue innovations in an untapped space; and 5) signs that a company will achieve commercial success from early on.

Venture Creation Firm Reveals Strategies For Launching New Companies & Forming Collaborations

David Klein, co founder and CEO of Click Therapeutics, discusses the new FDA SaMD guidance, the clear differences between companion apps and  SaMD, and gives insight into what to expect from this combination in the future.

New FDA SaMD Guidance Will Bring Monumental Changes to Industry

Edward Triebell, Commercial Executive Director for MRN Technologies, discusses the biggest digital trends in clinical research right now, how COVID-19 impacted the use of digital within sponsors and CROs, what the future of DCT services looks like, and much more.

DCT Opportunities in Clinical Research

In this podcast, Pharmaceutical Executive editors discuss the 2018 pharma trends, specifically biosimilars and eEnablement, and takeaways from the 2017 Veeva European Commercial Summit.

Leadership Tip from Julia Cheek, CEO of EverlyWell.

Episode 1: 2018 Pharmaceutical Trends

William Lewis, chairman and CEO of Insmed talks about the approval of the company’s drug Arikayce through the FDA’s Limited Population Pathway for Antibacterial and Antifungal Drugs, some ideas that he spoke about on the recent NORD panel about innovative and ethical partnerships, and Insmed’s pipeline and progress.

Episode 45: Getting Drug Approval Through FDA LPAD

The Pharm Exec Podcast goes beyond the pages of the Pharmaceutical Executive print magazine and PharmExec.com to bring the latest commercial insights to the C-suite through in-depth interviews. Podcast episodes examine current trends, key conferences, and critical topics in the industry.

Popular tracks by Pharmaceutical Executive Magazine